NEWS & EVENTS

 

Congratulations to our client Zealand Pharma A/S, now listed on NASDAQ

 
Congratulations to our client Zealand Pharma A/S, now listed on NASDAQ

17 August 2017

After announcing its intentions last month, Zealand Pharma A/S has gone public in the US to fund clinical trials and other projects.

Zealand Pharma, a Denmark based biotech focused on development of innovative peptide-based medicines, has been public on the Danish Aktieselskabet exchange since 2011, and since then its share price has risen by 50%.

After filing for an American IPO on July 6th 2017, Zealand is now listed on NASDAQ. The company is aiming to gain $75M (€63.5M) of funding, underwritten by Goldman Sachs and Morgan Stanley. This would bring Zealand’s market cap to $582M (€493M).

Read the full press release here.

Mewburn Ellis Attorneys Simon Kiddle, Graham ForrestSam Bailey and Sarah Brearley work with Zealand Pharma on their IP portfolio.